Highlights from SABCS 2021: T-DXd, KEYNOTE-355, PADA-1 & EMERALD

Peter Schmid, MD, PhD, FRCP, Barts Cancer Institute, London, UK, provides an overview of the latest treatment updates in breast cancer from the San Antonio Breast Cancer Symposium, including DESTINY-Breast03 (NCT03529110) which demonstrated the superiority of trastuzumab deruxtecan in patients with HER2+ advanced breast cancer, as well as the agents activity in patients with brain metastases. Prof. Schmid discusses the final results from the KEYNOTE-355 (NCT02819518) study presented at the San Antonio meeting evaluating pembrolizumab in advanced triple-negative breast cancer, as well as the PADA-1 study (NCT03079011) which investigated first-line aromatase inhibitor plus palbociclib with randomized switch to fulvestrant plus palbociclib upon detection of circulating ESR1 mutation in hormone-receptor-positive, HER2-negative metastatic breast cancer. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.